Sutherland Kester Maciver
Corporate Officer/Principal chez The University of Edinburgh
Profil
Sutherland Kester Maciver is the founder of Amoebics Ltd., which was founded in 1998.
He held the title of Chief Scientific Officer from 2010 to 2013.
Currently, he is a Professor at The University of Edinburgh.
Postes actifs de Sutherland Kester Maciver
| Sociétés | Poste | Début |
|---|---|---|
| The University of Edinburgh | Corporate Officer/Principal | 14/06/2010 |
Anciens postes connus de Sutherland Kester Maciver
| Sociétés | Poste | Fin |
|---|---|---|
Amoebics Ltd.
 Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Fondateur | 10/07/2013 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Amoebics Ltd.
Amoebics Ltd. Pharmaceuticals: MajorHealth Technology Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections. | Health Technology |
